Exploring The Therapeutic Potential Of Autologous Platelet-Rich Plasma Eyedrops For Dry Eye Patients Unresponsive To Autologous Serum Treatment
Published 2025
- 43rd Congress of the ESCRS
Reference: PO631
| Type: Free paper
Authors:
Neil Lagali* 1
, Maria Xeroudaki 2
, Petros Moustardas 1
, Edoardo Grosso 3
, Laetizia Mansutti 4
, Laura Gonzalez 5
, Ana Nolla Del Saz 5
, Jose Guell 5
, Emiliano Lepore 6
1Dept of Ophthalmology,Linköping University,Linköping ,Sweden, 2Eye Clinic,Region Östergötland,Linköping ,Sweden, 3Grupo Cidimu,Torino,Italy, 4Blue Eye Centri Oculistici,Milan,Italy, 5Institute of Ocular Microsurgery,Barcelona,Spain, 6RECornea Srl,Trieste,Italy
Purpose
To evaluate the efficacy of topical autologous platelet-rich plasma (PRP) for treating dry eye disease (DED) in patients unresponsive to autologous serum (AS) treatment.
Setting
This prospective study included 20 eyes (10 patients) with DED unresponsive to AS treatment at the out-patient clinic of King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Methods
Participants used PRP eyedrops six times daily for 6 weeks, followed by AS eyedrops for an additional 6 weeks. OSDI scores, conjunctival and corneal staining (NEI scores), tear film break-up time (TBUT), Schirmer test were evaluated at baseline, weeks 1, 4, 6, and 12. Subbasal nerve and dendritic cell density were evaluated at baseline, week 6 and 12 using HRT3 (Heidelberg Engineering, Heidelberg, Germany). Data were analyzed using a mixed-effects model with Bonferroni correction.
Results
After 6 weeks of PRP treatment, 100%, 83.3%, 72.2%, 66.7%, and 38.9% of eyes showed improvement in OSDI scores, conjunctival staining, corneal staining, TBUT, and Schirmer test, respectively. Significant improvements were observed in OSDI scores at weeks 1, 4, and 6 and in clinical signs, including conjunctival staining (weeks 4 and 6), corneal staining (week 1), and TBUT (weeks 1 and 6) (all P <0.05). No significant changes were observed in the Schirmer test, subbasal, and dendritic cell density.
Conclusions
Autologous PRP treatment demonstrated significant benefits in alleviating both symptoms and signs of DED in patients unresponsive to AS treatment.